June 9th, 2021 | 10:20 CEST
windeln.de, NSJ Gold, MorphoSys - High flyers of today and tomorrow
These are crazy times on the stock market and it is not easy to find the next high flyer. At the moment, even in Germany, there are gambler stocks, such as Adler Modemärkte. Markets are at their all-time highs and even if many cannot comprehend it, I guess you have to get used to it. Money that would otherwise have gone into government bonds flows into the equity markets, bringing a dividend yield instead of interest. Today we present three possible high flyers, whereby windeln.de has probably already gone too far.
time to read: 3 minutes | Author: Armin Schulz
ISIN: DE000WNDL201 , CA62973P1071 , DE0006632003
Table of contents:
Author
Armin Schulz
Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.
Tag cloud
Shares cloud
windeln.de - Pure gambling
windeln.de is regularly on the verge of insolvency. Being an online retailer, the Chinese business and the special effects in Corona times should have increased sales. But unlike Amazon and Co., the Company failed to seize the opportunity that presented itself. The self-imposed targets of double-digit growth were not achieved. It was only enough for a plus of 8.6%. The adjusted EBIT break-even target was postponed to 2022.
On April 1, the Company announced a loss of more than half of its share capital, after a capital increase in March at EUR 1.30, which brought EUR 1.4 million. Sales figures in the first quarter fell, as did EBIT compared to the same period last year. These figures cannot explain the sudden rise in the share price and make the windeln.de share a meme share.
A meme share is a term used among young investors to describe hyped shares for which no attention is paid to the fundamental data. Often this happens with stocks that have a high short ratio, or the market is very tight. In the case of windeln.de, the free float is only 16.3% or 2,293,787 shares (as of March 31). As a serious investor, you should stay away from this gamble, or if you really want to be in it, only put in play money.
NSJ Gold - Eagerly awaited results
A little later than initially expected, NSJ Gold has completed its drill program at the Golden Hills project. A total of 16 holes were drilled for a total of 1,263m. Samples were also taken along the high-grade gold zone, which is at least 88m long and is part of a 570m IP anomaly. Three other IP anomalies have been assayed, and they are now awaiting results from the 828 samples.
An analysis is expected in 3-6 weeks. However, the Company seems to be very pleased with the results, as on May 11 the Golden Hills project was expanded by 4km². The area is attractive because it is covered by alluvium, which can be considered a sign of mineral potential. There are structures containing copper oxides in the southeast of the new area and several prospects indicate potential.
The stock, which saw its all-time high of CAD 0.37 at the time of listing, has since moved back to the shares issue price at CAD 0.20. Based on the historical results and the significantly higher valued mining companies in the near vicinity, one can still speculate on a movement of the share at an early stage. Gold and copper prices have already risen, and if the results are positive, the stock will undoubtedly jump.
MorphoSys - Bottom found?
MorphoSys AG is a biopharmaceutical company and seeks to help patients suffering from cancer, inflammation and autoimmune diseases. With the announcement of the acquisition of Constellation for EUR 1.7 billion, the stock plummeted to EUR 60.30. Once again, the former darling of German shareholders made no friends among investors, as the acquisition was 70% above Constellation's share price.
However, CEO Kress portrays the move as transformative, as it will strengthen the Company's position in hematology-oncology. On Tuesday, the approval of Biogen's Alzheimer's drug boosted MorphoSys' share price. The reason is that the drug Gantenerumab from MorphoSys works according to the same procedures as the competitor product with the approval. That increases the Company's chances of obtaining regulatory approval.
So it is a stormy time for shareholders at the moment. Technically, the stock has formed a double bottom on May 11 and June 2. What would be necessary now is a rise and closing price above EUR 72.78. Then the picture for the share would clear up considerably. The downward trend would then also be stopped for the time being. The share has lost almost 50% of its value within a year and could slowly rebound. The stock should be on the watch list because there is a lot of potential.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.
The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.
